Table 2 Factors associated with the prescription of second-line therapy (bivariate analysis)
Variable, | Abiraterone plus prednisone N = 100 | Other 2nd line therapy N = 50 | p-value |
|---|---|---|---|
Age, mean (SD) | 73.5 (8.3) | 69.6 (8.2) | 0.008 |
ECOG*, n (%) | |||
0 | 21 (26.6) | 9 (20.5) | 0.329 |
1 | 48 (60.8) | 25 (56.8) | |
2 | 9 (11.4) | 10 (22.7) | |
3 | 0 (0.0) | 0 (0.0) | |
4 | 1 (1.2) | 0 (0.0) | |
Lifetime diabetes (yes), n (%) | 17 (17.0) | 9 (18.0) | 0.879 |
Lifetime cardiovascular disorders (yes), n (%) | 19 (19.0) | 8 (16.0) | 0.652 |
Lifetime hypertension (yes), n (%) | 52 (52.0) | 28 (56.0) | 0.643 |
Disease symptoms and/or signs* (yes), n (%) | 57 (60.0) | 34 (70.8) | 0.203 |
Anemia (yes), n (%) | 16 (16.5) | 15 (30) | 0.062 |
LDH increased (yes), n (%) | 45 (52.9) | 35 (77.8) | 0.006 |
Alkaline phosphatase increased (yes), n (%) | 32 (34.4) | 26 (55.3) | 0.018 |